What is the clinical evidence from this study?

Study design: Observational. Population: Eisenmenger syndrome in pregnancy (n=13). Intervention: Targeted drug therapy vs. Historical cases (literature review). Primary outcome: Maternal and neonatal mortality and morbidity.

What does this research mean for the field?

Targeted drug therapy improves maternal mortality and cardiac functional class in pregnant women with Eisenmenger syndrome. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 18, 2023

Successful Eisenmenger syndrome‐targeted drug therapy in pregnant women: a case series and literature review

Key Result

Targeted drug therapy in pregnant women with Eisenmenger syndrome improved cardiac function (92% class II/III at discharge) and may reduce the 24% maternal mortality seen in historical cases.

Study Design

Type

Observational (n=13)

Multicenter

Structured PICO

Does targeted drug therapy improve maternal and neonatal mortality and morbidity in pregnant women with Eisenmenger syndrome?

Population

13 pregnant women with Eisenmenger syndrome (ES) delivered between 2011 and 2021 at a tertiary referral hospital, alongside a literature review cohort of 72 cases.

Intervention

Eisenmenger syndrome-targeted drug therapy

Comparator

Historical/literature review cases characterized by a low rate of targeted drug use (28%)

Outcome

Maternal and neonatal mortality and morbidityhard clinical

Targeted drug therapy in pregnant women with Eisenmenger syndrome may improve cardiac functional class and reduce maternal and neonatal mortality compared to historical outcomes.

Abstract

OBJECTIVE: To clarify the real-world outcomes in pregnant women with Eisenmenger syndrome (ES) in the new therapeutic era and provide a literature review. DESIGN: Retrospective case and literature review. SETTING: Tertiary referral hospital (The Second Xiangya Hospital of Central South University). SAMPLE: Thirteen women with ES delivered between 2011 and 2021. METHODS: Respective study and literature reviews. MAIN OUTCOMES MEASURES: Maternal and neonatal mortality and morbidity. RESULTS: weeks, and the remaining 12 (92%) patients had preterm birth. 10/13 (77%) women gave birth to live infants, of which 9/10 (90%) were low birthweight infants with a mean birthweight of 1575 g. The infant mortality rate was 1/10 (10%). Cardiac functional class improved during pregnancy, probably due to therapy; 11/13 (85%) of the pregnant women were in cardiac functional level III/IV at admission and 12 (92%) were in cardiac functional class II/III at discharge. Our literature review identified 72 cases of pregnancy with ES from 11 studies, which were characterised by a low rate of targeted drug use (28%) and a high maternal mortality rate of 24% in the perinatal period. CONCLUSION: Our case series and literature review suggest that targeted drugs may be key to improving maternal mortality in ES.

Demander à l'IA

Bookmark

Demander à l'IA

Bookmark

Cite This Study

Chen et al. (Sat,) conducted a observational in Eisenmenger syndrome in pregnancy (n=13). Targeted drug therapy vs. Historical cases (literature review) was evaluated on Maternal and neonatal mortality and morbidity. Targeted drug therapy in pregnant women with Eisenmenger syndrome improved cardiac function (92% class II/III at discharge) and may reduce the 24% maternal mortality seen in historical cases.

synapsesocial.com/papers/6a1c61ca1567d2fc4d60030f https://doi.org/https://doi.org/10.1111/1471-0528.17427

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: